SCHEMBL402481

SCHEMBL402481

CC(=O)N1CCN(CCc2cc(F)cc(NC(=O)Nc3cccnc3)c2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 5/20 0.58
DRD2 P14416 4/20 0.58
CYP1A2 P05177 3/20 0.54
TAAR1 Q96RJ0 1/20 0.50
FAAH O00519 5/20 0.48
HTR1D P28221 1/20 0.45
HTR1B P28222 1/20 0.45
CYP2D6 P10635 2/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
TP53 P04637 1/20 0.45
CYP3A4 P08684 1/20 0.45
PKM P14618 1/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
THPO P40225 1/20 0.45
HIF1A Q16665 1/20 0.45
ALDH1A1 P00352 1/20 0.44
HTT P42858 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL399089 0.94 CYP1A2 (0.53) HTR1ADRD2CYP1A2TAAR1FAAH
SCHEMBL545356 0.90 CYP1A2 (0.56) HTR1ADRD2CYP1A2TAAR1FAAH
SCHEMBL401235 0.86 HTR1A (0.48) HTR1ADRD2CYP1A2FAAHHTR1D
SCHEMBL3188068 0.86 HTR1A (0.55) HTR1ADRD2CYP1A2TAAR1FAAH
SCHEMBL401535 0.85 HTR1A (0.50) HTR1ADRD2CYP1A2TAAR1FAAH
SCHEMBL402232 0.82 TAAR1 (0.54) HTR1ADRD2CYP1A2TAAR1FAAH
SCHEMBL399090 0.81 HTR1A (0.50) HTR1ADRD2CYP1A2TAAR1CYP2D6
SCHEMBL3189494 0.81 FAAH (0.56) HTR1ADRD2CYP1A2TAAR1FAAH
SCHEMBL545635 0.81 HTR1A (0.43) HTR1ACYP1A2HTR1DHTR1BALDH1A1
SCHEMBL402066 0.81 FAAH (0.54) HTR1ADRD2CYP1A2TAAR1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101617-B2 Disubstituted ureas and uses thereof in treating heart failure AMGEN, INC. (US) 2012-01-24 US disclosed
US-20090099198-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099198-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 HTR1A 3992/4885DRD2 4679/4885CYP1A2 4662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.